BCL2 and acute myeloid leukemia: Over the past decade, treatment strategies for acute myeloid leukemia (AML) have undergone substantial transformation, with a growing emphasis on combining targeted agents, such as BCL-2, FLT3, and IDH inhibitors, with conventional chemotherapy to enhance patient outcomes [1,2].